Research Advantages in Marine Microbial Acetylcholinesterase Inhibitors Against Alzheimer’s Disease: An Overview

Abstract

Public health is significantly threatened by neurodegenerative disorders, especially Alzheimer's disease (AD). A significant cause of dementia is Alzheimer's disease (AD), accounting for up to 75 percent of all cases of dementia. Degeneration of neurons and synapses, primarily characterized by cholinergic dysfunction, are the pathophysiological processes defined for AD progression. This function makes inhibitors of acetylcholinesterase (AChEi) the main class of drugs commonly used to treat the dementia process of AD. The symptomatic progress of Alzheimer's disease (AD) remains a highly viable target since the cholinergic deficiency is a clear and early finding in AD. More and more marine compounds have been isolated from marine animals for the medicinal treatment of neurological conditions, including Alzheimer's disease (AD). Significant producers of AChEIs are fungi and bacteria. Alkaloids, terpenoids, phenylpropanoids, and steroids are the active components in fermentation products. In this review, we provide an overview of the different marine microbe-derived AChEIs and their producing strains.